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MaBACKGROUND Type 2 diabetes (T2D) and obesity are associated with nonalcoholic fatty liver disease, cardiomyopathy,
and cardiovascular mortality. Both show stronger links between ectopic and visceral fat deposition, and an increased
cardiometabolic risk compared with subcutaneous fat.
OBJECTIVES This study investigated whether lean patients (Ln) with T2D exhibit increased ectopic and visceral fat
deposition and whether these are linked to cardiac and hepatic changes.
METHODS Twenty-seven obese patients (Ob) with T2D, 15 Ln-T2D, and 12 normal-weight control subjects were
studied. Subjects underwent cardiac computed tomography, cardiac magnetic resonance imaging (MRI), proton and
phosphorus MR spectroscopy, and multiparametric liver MR, including hepatic proton MRS, T1- and T2*-mapping yielding
“iron-corrected T1” [cT1].
RESULTS Diabetes, with or without obesity, was associated with increased myocardial triglyceride content (p ¼ 0.01),
increased hepatic triglyceride content (p ¼ 0.04), and impaired myocardial energetics (p ¼ 0.04). Although cardiac
structural changes, steatosis, and energetics were similar between the T2D groups, epicardial fat (p ¼ 0.04), hepatic
triglyceride (p ¼ 0.01), and insulin resistance (p ¼ 0.03) were higher in Ob-T2D. Epicardial fat, hepatic triglyceride, and
insulin resistance correlated negatively with systolic strain and diastolic strain rates, which were only signiﬁcantly
impaired in Ob-T2D (p < 0.001 and p ¼ 0.006, respectively). Fibroinﬂammatory liver disease (elevated cT1) was only
evident in Ob-T2D patients. cT1 correlated with hepatic and epicardial fat (p < 0.001 and p ¼ 0.01, respectively).
CONCLUSIONS Irrespective of body mass index, diabetes is related to signiﬁcant abnormalities in cardiac structure,
energetics, and cardiac and hepatic steatosis. Obese patients with T2D show a greater propensity for ectopic and visceral
fat deposition. (J Am Coll Cardiol 2016;68:53–63) © 2016 by the American College of Cardiology Foundation. Published
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ABBR EV I A T I ON S
AND ACRONYMS
1H-MRS = proton magnetic
resonance spectroscopy
31P-MRS = phosphorus
magnetic resonance
spectroscopy
ATP = adenosine triphosphate
BMI = body mass index
BP = blood pressure
CT = computed tomography
cT1 = iron-corrected T1
HOMA-IR = homeostasis model
assessment of insulin
resistance
Ln-T2D = lean patients with
type 2 diabetes
LV = left ventricular
MR = magnetic resonance
MRI = magnetic resonance
imaging
NAFLD = nonalcoholic fatty
liver disease
Ob-T2D = obese patients with
type 2 diabetes
PCr = phosphocreatine
T2D = type 2 diabetes
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54T ype 2 diabetes (T2D) and obesity areboth associated with nonalcoholicfatty liver disease (NAFLD), cardio-
myopathy (1,2), and increased cardiovascular
mortality (3,4). The incidence of T2D con-
tinues to increase, driven predominantly by
the obesity epidemic. Although obesity is
likely to be a strong contributor to diabetic
cardiomyopathy (5), many patients with dia-
betic cardiomyopathy have normal body
mass index (BMI), suggesting that diabetes
and obesity may have different mechanisms
by which they mediate cardiovascular change
and that diabetic cardiomyopathy may occur
in patients with T2D without obesity. Further-
more, evidence suggests that distribution of
excess fat is an important determinant of car-
diovascular risk, and ectopic and visceral
adiposity confer a much higher risk than sub-
cutaneous adiposity (6,7).
Ectopic and visceral fat storage may be
linked to insulin resistance, and it is widely
known that insulin resistance is the strongest
predictor of development of diabetes (8).
Increasing evidence points to a strong asso-
ciation between insulin resistance and non-
ischemic heart failure (9), although there arediffering opinions regarding whether this relation-
ship is of a protective or pathological nature (10–12).
Thus, the presence of ectopic and visceral fat depo-
sition in patients with T2D even in the absence of a
global increase in total body fat may potentially play a
signiﬁcant role in this association. Assessing body
composition is, therefore, likely to be more important
in patients with T2D than simple metrics of obesity.
Liver fat is considered a key feature of ectopic fat
associated with dysfunctional adipose tissue and
visceral fat deposition (13), and there is also growing
interest in the imaging of epicardial adipose tissue as
a proxy measure of visceral fat.SEE PAGE 64Epicardial adipose tissue, a form of visceral fat,
may affect the underlying myocardium by secreting
a wide range of adipokines (14). Furthermore,
excess liver fat has been shown to be accompanied by
cardiac structural and functional changes (15).
Computed tomography (CT) allows quantiﬁcation of
epicardial fat volume, and proton magnetic reso-
nance spectroscopy (1H-MRS) allows quantiﬁcation
of lipid content in the liver and the heart. Multi-
parametric magnetic resonance (MR) of the liver,
including 1H-MRS for assessment of steatosis and T1
and T2* mapping (yielding iron corrected T1 [cT1])(16), allows noninvasive quantiﬁcation of liver
fat and identiﬁcation of the presence of hepatic
ﬁbroinﬂammatory disease with a high diagnostic ac-
curacy (16).
Myocardial energetic compromise is an important
feature of both the diabetic (17) and the nondiabetic
obese heart (5). However, changes in cardiac energy
metabolism in lean patients with diabetes have not
been previously studied. Myocardial phosphocreatine
to adenosine triphosphate concentration ratio (PCr/
ATP) is a sensitive indicator of the myocardial energy
status, and phosphorus magnetic resonance spec-
troscopy (31P-MRS) allows noninvasive assessment of
the PCr/ATP.
Our primary aim was to test the hypothesis that
lean patients (Ln) with T2D exhibit increased ectopic
and visceral fat deposition. Our secondary aim was to
test whether or not ectopic and visceral adiposity in
diabetes is associated with insulin resistance and
cardiac and hepatic changes. We used cardiac CT,
multiparametric liver magnetic resonance imaging
(MRI), cardiac MRI, 1H-MRS, and 31P-MRS to assess
and compare epicardial, hepatic, and myocardial fat
deposition; hepatic ﬁbroinﬂammatory changes; and
cardiac structure, function, and energetics in lean and
obese patients (Ob) with T2D and in control subjects
without diabetes.
METHODS
The study was approved by the National Research
Ethics Committee (Ref 13/SW/0257), and informed
written consent was obtained from each participant.
Patients were recruited from general practice sur-
geries in Oxfordshire, United Kingdom. A total of 27
Ob-T2D, 15 Ln-T2D, and 12 healthy normal weight
control subjects were recruited to the study. We have
previously reported changes in myocardial ener-
getics, triglyceride content, and left ventricular (LV)
structure and function in patients with diabetes
compared with healthy volunteers (18,19). Using this
database, and expanding the data with novel
recruitment of 12 healthy volunteers to the study,
here we report a comparison of the changes in these
cardiac features in 2 subgroups of patients with
diabetes (obese and lean) compared with healthy
volunteers. Additionally, we report an analysis of
epicardial fat volumes, liver triglyceride content, and
liver ﬁbroinﬂammatory changes.
EXCLUSION CRITERIA. Subjects were excluded if
they had a previous diagnosis of cardiovascular or
liver disease, hypertension (resting systolic blood
pressure >140 mm Hg and diastolic blood pressure
>90 mm Hg), contraindications to MRI, ischemic
FIGURE 1 Study Protocol for Patients With T2D
Assessment of
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(Medical history;
physical
examination; ECG;
blood tests)
Optional Cardiac
CT Scan
(Epicardial fat
volume and
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T2* mapping
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31P-MRS
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ATP)
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Suitability of patients with type 2 diabetes (T2D) was assessed during the ﬁrst hospital visit. Those patients who consented to have a cardiac computed tomography (CT)
scan were then invited for the second hospital visit. The third hospital visit included magnetic resonance imaging (MRI) and magnetic resonance spectroscopy scans (3T).
Multiparametric liver MRI included proton magnetic resonance spectroscopy (1H-MRS) for hepatic triglyceride; T1 and T2* mapping yielded iron-corrected T1 (cT1). This
was followed by cardiac magnetic resonance, which included cine imaging to assess left ventricular (LV) volumes, mass, and ejection fraction; myocardial tagging for
assessment of peak circumferential systolic strain and diastolic strain rate; cardiac 1H-MRS for myocardial triglyceride; and late gadolinium enhancement (LGE) imaging
for exclusion of myocardial scarring. Control subjects underwent identical MRI protocols. 31P-MRS ¼ phosphorus magnetic resonance spectroscopy; ECG ¼ electro-
cardiogram; HLA ¼ horizontal long axis; PCr/ATP ¼ myocardial phosphocreatine to adenosine triphosphate concentration ratio; SA ¼ short axis.
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55changes on 12-lead electrocardiography, or renal
impairment (estimated glomerular ﬁltration rate <30
ml/min/1.73 m2); if they were tobacco smokers; if
their alcohol intake was above 21 units in a week for
men or 14 units for women; or if they were insulin
dependent.
Control subjects had no history of heart disease,
diabetes mellitus (fasting glucose level $6.7 mmol),
or hypertension and were not taking any medications.
Study assessments were carried out on a single visit
for the healthy control subjects and over 2 or 3
visits for patients with T2D, depending on indi-
viduals’ consent for attending cardiac CT assessments
(Figure 1).
ANTHROPOMETRIC MEASUREMENTS. Height and
weight were recorded and BMI was calculated.
Brachial blood pressure was recorded as an average of
3 supine measures taken over 10 min (DINAMAP-
1846-SX, Critikon Corp., Tampa, Florida). Fasting
venous blood was drawn for glucose, insulin, hemo-
globin A1c (HbA1c), triglycerides, renal function, liver
function, and free fatty acids. Insulin levels and
HbA1c were checked in the patients with diabetes, but
not in control subjects. Homeostasis model assess-
ment of insulin resistance (HOMA-IR) was used to
evaluate insulin resistance using the followingequation: (fasting serum insulin [mU/l] fasting
plasma glucose [mmol$l1])/22.5 (20).
CARDIAC CT. Coronary CT . An optional scan of cor-
onary computed tomographic angiography (CCTA)
was offered to patients with diabetes to exclude
obstructive coronary artery disease (>50% of luminal
stenosis) and for assessment of epicardial fat vol-
umes. CCTA was performed with a GE VCT 64 slice
scanner (GE Healthcare, Little Chalfont, United
Kingdom) and a Snapshot Pulse protocol with pro-
spective electrocardiographic triggering. Participants
received beta-blockade (intravenous metoprolol) and
sublingual glyceryl trinitrate prior to the scan to
achieve a heart rate of <65 beats/min. During
the CCTA acquisition, 70 ml of iodinated contrast
(Niopam 370, Bracco, High Wycombe, United
Kingdom) was injected at a rate of 6 ml/s followed
by a 50-ml saline ﬂush. The scan covered a region
from 1 to 2 cm above the left main coronary artery to
1 to 2 cm below the myocardial apex in a single breath
hold.
Ep icard ia l fat volume quant iﬁcat ion . CT images
were reconstructed using medium-soft kernel (stan-
dard) with slice thickness of 0.625 mm and then
transferred to a dedicated workstation for image
processing (TeraRecon Aquarius iNtuition version
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adipose tissue volume was quantiﬁed using contrast-
enhanced CT images. The layer of the epicardium was
manually traced, and a 3-dimensional image was
constructed using a semiautomated method. The
volume was then calculated by a blinded operator
(S.T.) and deﬁned as the tissue with attenuation
of 190 to 30 HU.
CARDIAC MR. All LV imaging was performed on a
3.0-T MR system (Siemens, Erlangen, Germany).
Images for LV volumes and diastolic function were
acquired using a steady-state free precession
sequence and analyzed using cmr42 (Circle Cardio-
vascular Imaging Inc., Calgary, Alberta, Canada). To
determine midventricular systolic circumferential
strain and diastolic strain rate, myocardial tagging
was performed (21,22). Tagged images were analyzed
using Cardiac Image Modeller software (CimTag2D
version 7, Auckland Medical Research, Auckland,
New Zealand). Semiautomated analysis was per-
formed by aligning a grid to the myocardial tagging
planes at end-diastole. A more detailed description of
the MRI methods and MR acquisition parameters is
included in the Online Appendix.
31P-MAGNETIC RESONANCE SPECTROSCOPY. 31P-MRS
was performed to obtain the rest PCr/ATP from a voxel
placed in themidventricular septum, with the subjects
lying prone with their heart over the center of the
31P heart/liver coil in the isocenter of the magnet.
31P-MRS post-processing analysiswas performed using
in-house software within Matlab version R2012a
(Mathworks, Natick, Massachusetts). A more detailed
description of the cardiac 31P-MRS acquisition param-
eters is included in the Online Appendix.
CARDIAC AND LIVER 1H-MRS. Myocardial 1H-MRS
was obtained from the midinterventricular septum.
Liver triglyceride content was measured using
1H-MRS, avoiding vascular and biliary structures.
Spectroscopic acquisitions were performed using
electrocardiographic trigger. Water-suppressed spec-
tra were acquired to measure myocardial and liver
triglyceride content, and spectra without water sup-
pression were acquired and used as an internal
standard. Spectra were analyzed using Matlab and the
AMARES algorithm in the Java-based Magnetic
Resonance User Interface. Myocardial and liver tri-
glyceride contents were calculated as a percentage
relative to water: (signal amplitude of lipid/signal
amplitude of water)  100. A more detailed descrip-
tion of the 1H-MRS acquisition parameters is included
in the Online Appendix.
LIVER MRI. The liver multiparametric MR protocol
has been previously described (16). MR scans wereperformed using a 3-T scanner (Tim Trio, Siemens).
Transverse abdominal T1 and T2* MR maps were ac-
quired for the estimation of extracellular ﬂuid and
liver iron, respectively. Patients fasted overnight
prior to their MRI scans.
cT1 AND FIBROINFLAMMATORY LIVER DISEASE. T1
relaxation time increases with increases in extracel-
lular ﬂuid, such as in ﬁbrosis and inﬂammation.
However, the presence of iron, which can be accu-
rately measured from T2* maps, has an opposing
effect on the T1. An algorithm has been created that
allows for the bias introduced by elevated iron to
be removed from the T1 measurements, yielding
the cT1.
LiverMultiScan (Perspectum Diagnostics, Oxford,
United Kingdom) is a software product speciﬁcally
developed to measure cT1 from T1 and T2* maps. For
this study, the LiverMultiScan was used to analyze
anonymized images by investigators blinded to the
clinical data (C.K., M.P.). cT1 was measured in a sin-
gle, operator-deﬁned region of interest away from
vascular and biliary structures.
STATISTICAL ANALYSIS. All statistical analysis was
performed with commercially available software
packages (SPSS Statistics version 20, IBM, Armonk,
New York). All data were checked for normality
using the Kolmogorov-Smirnov test and presented as
mean  SD. Comparisons between the 3 groups were
performed by 1-way analysis of variance with post hoc
Bonferroni corrections. Bivariate correlations were
performed using the Pearson or Spearman method as
appropriate. The Student t test was used for com-
parison of normally distributed datasets where data
were obtained for only 2 T2D groups. Signiﬁcance was
deﬁned as p < 0.05.
RESULTS
PARTICIPANT CHARACTERISTICS. Demographic,
clinical, and biochemical data are shown in Table 1. A
total of 27 Ob-T2D patients (14 males, age 56 
8 years, BMI 33  3 kg/m2, mean diabetes duration
6.1  4.7 years, mean HbA1c 7.7  1.4%), 15 Ln-T2D
patients (9 males, age 56  9 years, BMI 23 
2 kg/m2, mean diabetes duration 6.6  6.5 years,
mean HbA1c 7.4  0.9%), and 12 healthy volunteers
(8 males, age 50  10 years, BMI 23  2 kg/m2) were
recruited. Participants in all groups were of similar
age and sex, and there were no signiﬁcant differences
in blood pressure, diabetes duration, diabetes treat-
ment, or metabolic proﬁle between the 2 diabetes
groups (Table 1). Systolic blood pressure was statisti-
cally higher in participants with T2D compared with
control subjects, although it remained within normal
TABLE 1 Clinical and Biochemical Characteristics
Normal Control
Subjects
(n ¼ 12)
Lean T2D
Patients
(n ¼ 15)
Obese T2D
Patients
(n ¼ 27) p Value
Age, yrs 50  10 56  9 56  8 0.163
BMI, kg/m2 23  3 23  2 33  3* <0.001
Male 58 60 40 0.35
Diabetes duration, yrs — 6.1  4.7 6.6  6.5 0.78
Heart rate, beats/min 66  10 65  7 69  7 0.34
Systolic blood pressure, mm Hg 118  14 131  7† 130  9† 0.002
Diastolic blood pressure, mm Hg 70  8 76  7 76  7 0.05
Plasma fasting glucose, mmol/l 5.0  0.5 8.1  3.0† 9.5  3.3† 0.001
Glycated hemoglobin, % — 7.4  0.9 7.7  1.4 0.22
Hematocrit, % 43  3 42  3 43  3 0.81
Insulin, pmol/l — 107  142 218  255 0.03
HOMA-IR, % — 1.26  0.70 5.45  5.6 0.03
Plasma triglycerides, mmol/l 0.92  0.38 1.87  1.81 1.75  0.81 0.15
Plasma free fatty acids, mmol/l 0.59  0.42 0.61  0.20 0.67  0.43 0.82
Total cholesterol, mmol/l 4.7  1.0 3.8  0.8 4.1  1.0 0.10
HDL, mmol/l 1.55  0.56 1.24  0.29 1.20  0.31† 0.03
LDL, mmol/l 2.93  0.46 1.85  0.59† 2.12  0.82† 0.002
Medications
Metformin — 14 (93) 23 (85) 0.45
Sulfonylurea — 4 (27) 12 (44) 0.27
Aspirin — 2 (13) 7 (26) 0.35
Statin — 8 (60) 19 (70) 0.51
ACE-I — 7 (47) 10 (37) 0.56
Values are mean  SD, %, or n (%). *p < 0.05 versus lean T2D and control subjects with Bonferroni correction.
†p < 0.05 versus control subjects with Bonferroni correction.
ACE-I ¼ angiotensin-converting enzyme inhibitors; BMI ¼ body mass index; HDL ¼ high-density lipoprotein;
HOMA-IR ¼ homeostasis model assessment of insulin resistance; LDL ¼ low-density lipoprotein; T2D ¼ type 2
diabetes.
TABLE 2 CMR and Cardiac MRS Findings
Control
Subjects
(n ¼ 12)
Lean T2D
Patients
(n ¼ 15)
Obese T2D
Patients
(n ¼ 27) p Value
LV end-diastolic volume, ml 145  40 124  33 126  25 0.15
LV ejection fraction, % 68  5 73  7 68  8 0.11
LV mass, g 91  30 123  33* 119  28* 0.01
LV mass index, g/m2 48  11 66  15* 57  10 0.001
LV mass to LV end-diastolic
volume, g/ml
0.63  0.13 0.95  0.26* 0.90  0.20* <0.001
Peak systolic circumferential strain,
negative (), %
18.1  2.1 16.5  2.6 13.4  3.6† <0.001
Peak circumferential diastolic
strain rate, s1
74  20 68  19 56  26† 0.006
Myocardial PCr/ATP ratio 2.08  0.40 1.75  0.29* 1.64  0.32* 0.003
Myocardial triglyceride, %
(lipid/water ratio)
0.48  0.28 1.14  0.66* 1.22  0.91* 0.004
Values are mean  SD. *p < 0.05 versus control subjects with Bonferroni correction. †p < 0.05 versus lean
patients with T2D and control subjects with Bonferroni correction.
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricular; MRS ¼magnetic resonance spectroscopy; PCr/ATP ¼
phosphocreatine to adenosine triphosphate concentration ratio; T2D ¼ type 2 diabetes.
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57limits. A total of 77% of the patients with diabetes
were on statin therapy, and patients with diabetes
therefore had lower low-density lipoprotein choles-
terol levels compared with control subjects.
CARDIAC GEOMETRY AND FUNCTION. Cardiac MR
results for LV volumes and function are summarized
in Table 2. LV volumes and ejection fraction were
similar between the Ln- and Ob-T2D groups and
control subjects. However, although LV ejection
fractions were not signiﬁcantly different across the
groups, more subtle functional changes with impair-
ment in peak circumferential systolic strain and
diastolic strain rates were evident in Ob-T2D
compared with control subjects (p ¼ 0.001 and
p ¼ 0.006, respectively) and also compared with
Ln-T2D (p ¼ 0.015 and p ¼ 0.026, respectively). As we
have previously shown, diabetes was associated with
LV concentric hypertrophy (19), characterized by
increased LV mass to volume ratio and increased LV
mass, in both diabetes groups compared with control
subjects.
CARDIAC METABOLIC PHENOTYPE. Cardiac 1H- and
31P-MRS results for myocardial triglyceride and
energetics are summarized in Table 2. Diabetes was
associated with cardiac steatosis even in the absence
of obesity (Ln-T2D vs. control subjects; p ¼ 0.01), and
there was no signiﬁcant difference in myocardial tri-
glyceride levels between the Ob- and Ln-T2D groups.
PCr/ATP was signiﬁcantly reduced in both T2D groups
compared with control subjects (Ob-T2D vs. control
subjects; p ¼ 0.002; Ln-T2D vs. control subjects;
p ¼ 0.043). There was no signiﬁcant difference in
myocardial PCr/ATP ratio between the Ob- and Ln-T2D
groups (p ¼ 0.92). There were no signiﬁcant correla-
tions between the myocardial PCr/ATP ratio and the
markers of ectopic and visceral adiposity, such as
hepatic triglyceride content (r ¼ 0.17; p ¼ 0.36), or
with epicardial fat volume (r ¼ 0.23; p ¼ 0.27).
EPICARDIAL FAT. Epicardial fat volume assessment
was carried out in 33 patients (79% of the study
patients) who have opted for CCTA. The Ob-T2D group
had higher epicardial fat volumes compared with the
Ln-T2D group (96  40 cm3 vs. 71  21 cm3; p ¼ 0.04).
Figure 2 shows representative images of epicardial fat
volume in an LN- and an Ob-T2D patient.
HEPATIC STEATOSIS, IRON CONTENT, FIBROSIS,
AND INFLAMMATION. Liver enzymes and multi-
parametric liver MRI results for hepatic steatosis,
ﬁbrosis, and hemosiderosis are summarized in
Table 3. Similar to cardiac steatosis, diabetes, even in
the absence of obesity, was associated with hepatic
steatosis (hepatic triglyceride content in Ln-T2D vs.
control subjects; p ¼ 0.044); however, hepatic
FIGURE 2 Representative Examples of CT Epicardial Fat Volumes in a Lean and an Obese Patient With T2D
(Top) Lean patient with T2D with epicardial fat volume 37.75 cm3. (Bottom) Obese patient with T2D with epicardial fat volume
192.59 cm3. Abbreviations as in Figure 1.
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58steatosis was most marked in the Ob-T2D group:
approximately 2-fold higher than in the Ln-T2D group
(Ob-T2D vs. Ln-T2D; p ¼ 0.012) and approximately
4-fold higher than in control subjects (Ob-T2D vs.
control subjects; p ¼ 0.005). Iron levels were normal
across the groups.
Mean cT1 was highest in the Ob-T2D group, where
the highest levels of hepatic triglyceride content were
detected. The numeric differences in mean cT1 be-
tween Ln-T2D and control subjects did not reach
statistical signiﬁcance (p ¼ 0.245), whereas cT1 in the
Ob-T2D group was signiﬁcantly increased compared
with the Ln-T2D group (p ¼ 0.004) and control sub-
jects (p < 0.001), indicating signiﬁcant ﬁbroin-
ﬂammatory liver disease in this group. Figure 3
represents differences in cardiac function, hepatic
steatosis, and hepatic cT1 across the study cohorts.
There was a positive correlation between the hepatic
cT1 and hepatic triglyceride content (r ¼ 0.71;
p < 0.001). Importantly, despite the presence of
hepatic steatosis and ﬁbroinﬂammatory changes in
the Ob-T2D group, there was no signiﬁcant differencein liver enzymes compared with control subjects, and
there was no association between liver cT1 and liver
enzymes. Alanine aminotransferase levels were only
minimally elevated (>45 to <80 IU/l) in 5 Ob-T2D
patients and were normal in all other patients. The
Central Illustration shows representative liver 1H-MR
spectra, and a liver T1 map in a volunteer and in a lean
and an obese patient with T2D.
RELATIONSHIP OF INSULIN RESISTANCE, ECTOPIC
FAT ACCUMULATION, AND CARDIAC FUNCTION.
Insulin resistance, measured by HOMA-IR, was
signiﬁcantly higher in the Ob-T2D compared with the
Ln-T2D group (p ¼ 0.03). When investigating all T2D
subjects, there was a positive correlation between
the HOMA-IR and epicardial fat volumes (r ¼ 0.47;
p ¼ 0.029), hepatic triglyceride (r ¼ 0.39; p ¼ 0.046),
and hepatic cT1 (r ¼ 0.58; p ¼ 0.001), and there was a
negative correlation between HOMA-IR and peak
circumferential systolic strain (r ¼ 0.52; p ¼ 0.003).
Furthermore, peak circumferential systolic strain also
correlated negatively with the hepatic triglyceride
(r ¼ 0.49; p ¼ 0.001) and epicardial fat volumes
FIGURE 3 Differences in Cardiac Function, Hepatic Steatosis, and Hepatic cT1 Among the Study Cohorts
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(A) Peak circumferential systolic strain; (B) diastolic strain rate; (C) hepatic triglyceride content (%); and (D) hepatic corrected T1 map (ms). The dots
indicate values outside the interquartile range. Abbreviations as in Figure 1.
TABLE 3 Liver Assessments
Control
Subjects
Lean T2D Patients
(n ¼ 15)
Obese T2D Patients
(n ¼ 27) p Value
Liver enzymes
Bilirubin, umol/l 12  4 12  6 11  4 0.48
ALT, IU/l 22  9 30  22 36  17 0.18
ALP, IU/l 145  29 150  50 163  46 0.47
Albumin, g/l 44  3 45  2 46  3 0.53
Multiparametric liver MRI
cT1, ms 753  45 821  67 924  116* <0.001
Hepatic triglyceride, %
(lipid/water ratio)
3.8  3.6 7.6  4.6† 14.8  8.4* <0.001
T2*, ms 20  4 20  4 18  5 0.41
Liver iron, mg/g 1.3  0.12 1.34  0.13 1.33  0.19 0.99
Values are mean  SD. *p < 0.05 versus lean patients with T2D and control subjects with Bonferroni correction.
†p < 0.05 versus control subjects with Bonferroni correction.
ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; cT1 ¼ corrected T1; LIF ¼ liver inﬂammation and
ﬁbrosis score; MRI ¼ magnetic resonance imaging; other abbreviations as in Table 2.
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59(r ¼ 0.53; p ¼ 0.004). Similarly, diastolic strain rate
correlated negatively with hepatic triglyceride
(r ¼ 0.54; p < 0.001) and epicardial fat volumes
(r ¼ 0.59; p ¼ 0.001). Myocardial triglyceride did not
correlate with epicardial fat volumes (r ¼ 0.36;
p ¼ 0.103) or with hepatic triglyceride (r ¼ 0.23;
p ¼ 0.168).
DISCUSSION
This study demonstrates for the ﬁrst time that dia-
betes, even in the absence of obesity, is associated
with signiﬁcant cardiac structural and metabolic ab-
normalities, whereas signiﬁcant functional changes,
such as reductions in peak systolic strain and diastolic
strain rates, are only evident in obese patients with
diabetes. Furthermore, we show that those patients
with diabetes who are also obese have higher
CENTRAL ILLUSTRATION The Role of Fat Deposition in Type 2 Diabetes: Examples of 1H-MRS, and Transaxial Liver
ShMOLLI T1 Map in a Healthy Volunteer, a Lean Patient With T2D, and an Obese Patient With T2D
Levelt, E. et al. J Am Coll Cardiol. 2016;68(1):53–63.
(A) Proton magnetic resonance spectroscopy (1H-MRS) of healthy volunteer with hepatic triglyceride (TG) 2.5%. (B) 1H-MRS of lean patient with type 2 diabetes (T2D)
with hepatic TG 7.6%. (C) Obese patient with T2D with hepatic TG 16.1%. (D) Healthy volunteer with liver Shortened Modiﬁed Look-Locker Inversion recovery
(ShMOLLI) T1 map with corrected T1 (cT1) 748 ms. (E) Lean patient with T2D with liver ShMOLLI T1 map with cT1 772 MS. (F) Obese patient with T2D with liver ShMOLLI T1
map with cT1 1244 ms. BMI ¼ body mass index.
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60epicardial fat volumes, signiﬁcant NAFLD, and higher
insulin resistance. Importantly, we demonstrate here
that the degree of hepatic and epicardial fat accu-
mulation is associated with cardiac contractile
dysfunction in diabetes. We conﬁrm the ﬁndings of
previous studies showing the association between
epicardial fat deposition and insulin resistance
(23,24); moreover, we also demonstrate that there is
an association between ﬁbroinﬂammatory liver dis-
ease and insulin resistance in patients with diabetes.
The correlation of systolic strain and diastolic
strain rates with hepatic and epicardial fat and
insulin resistance suggests a link between these in
patients with diabetes. However, the causality of
these relationships will need to be investigated in
future studies.
Finally, as is widely known, the spectrum of
NAFLD ranges from fatty liver alone to nonalcoholic
steatohepatitis (25). We show here that diabetes, evenin the absence of obesity, is associated with hepatic
steatosis at the mild end of the liver disease spec-
trum, but not with signiﬁcant ﬁbroinﬂammatory liver
disease. Importantly, using multiparametric liver
imaging, we show that signiﬁcant NAFLD and nonal-
coholic steatohepatitis are present in asymptomatic
patients with T2D with minor or no alanine amino-
transferase elevation. This technique promises to
answer a pressing need for a reliable, quick, and
noninvasive screening, staging, and monitoring tool
for diabetic liver disease.
ECTOPIC AND VISCERAL FAT, INSULIN RESISTANCE,
AND THE HEART. Our results suggest that Ln-T2D
patients are likely to have less pronounced insulin
resistance, lower levels of epicardial and hepatic fat
accumulation, and better cardiac function than
Ob-T2D patients. It is now widely accepted that adi-
pose tissue is a dominant regulator of lipid and
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61glucose metabolism (26). Multiple studies support the
concept that insulin resistance is prompted, and
sustained by, dysregulated fat tissue (27–29). In
addition, insulin resistance and ectopic adiposity are
associated with an even greater cardiovascular risk
(30,31), and obese subjects with T2D are at high risk of
developing ectopic adiposity (32). There are many
molecular mechanisms that may contribute to the
association between insulin resistance and non-
ischemic cardiomyopathy (9). These include meta-
bolic inefﬁciency (33), impaired vascular function
(34), inﬂammation, and mitogenic actions of insulin
on myocardium leading to changes of left ventricular
geometry (35).
Epicardial adipose tissue has dichotomous func-
tional characteristics, both adverse and protective,
interacting locally with the coronary arteries and the
myocardium through paracrine and vasocrine path-
ways. Under physiological conditions, epicardial fat
supplies heat to the myocardium and exerts a pro-
tective effect on the coronary arteries (23,36). Its
pathological increase, and the coexistence of other
metabolic and hemodynamic abnormalities, turn it
into an adverse lipotoxic, prothrombotic, and proin-
ﬂammatory organ (31).
In our study, the dissociation of myocardial stea-
tosis from epicardial and liver fat is in keeping with a
previous study in patients without diabetes and
supports the hypothesis that myocardial lipid accu-
mulation may represent a separate entity that is
inﬂuenced by factors beyond visceral adiposity (37).
Rijzewijk et al. (38) and McGavock et al. (39) previ-
ously demonstrated myocardial steatosis in patients
with T2D. Furthermore, McGavock et al. (39) per-
formed 1H-MRS in a large cohort of patients with T2D
and were the ﬁrst to show that hepatic triglyceride
was not predictive of myocardial triglyceride (38).
Thus, elevated levels of intracellular triglyceride in
hepatocytes do not necessarily reﬂect elevated tri-
glyceride levels in cardiac myocytes in T2D, which we
conﬁrm here.
ECTOPIC FAT AND THE LIVER. Our results suggest
that Ln-T2D patients are more likely to have simple
steatosis and Ob-T2D patients are more likely to have
steatohepatitis. Our study is the ﬁrst to date to non-
invasively assess the severity of liver damage using a
multiparametric MRI protocol in Ln- and Ob-T2D pa-
tients and to determine the effect of ﬁbroin-
ﬂammatory liver disease on the cardiac phenotype.
We have demonstrated that asymptomatic Ob-T2D
patients have signiﬁcantly higher liver cT1 compared
with Ln-T2D patients and healthy volunteers. This
would indicate a greater burden of ﬁbroinﬂammatoryliver disease in this group of patients who should be
prioritized for NAFLD screening in clinical practice.
Importantly, these differences were present on im-
aging but not on alanine aminotransferase levels,
suggesting that alanine aminotransferase alone is not
a sensitive screening test for the presence of NAFLD
in these patients. It has previously been shown
that liver cT1 is associated with ﬁbrosis (16) and also
that it can differentiate simple steatosis from steato-
hepatitis (40–42).
NAFLD is deﬁned as excessive fat accumulation in
the liver (>5.6%) (43); it is among the leading causes
of death in T2D (44) and is linked to hepatic insulin
resistance (45). Despite this strong association and
the emergence of NAFLD as a novel cardiovascular
risk factor, only a few studies have addressed the
presence of myocardial structural and functional
changes in patients with NAFLD. Speciﬁcally, NAFLD,
diagnosed either by ultrasonography or by liver
biopsy, was shown to be associated with a higher
prevalence of reduced coronary ﬂow reserve (46),
coronary calciﬁcation (47), impairment in diastolic
function (48), concentric LV remodeling, and reduced
longitudinal shortening (49).
STUDY LIMITATIONS. This study is limited by a
relatively small sample size. Of 42 patients with T2D,
9 patients (21%) did not consent to have CCTA per-
formed, and it is possible that occult coronary artery
disease could be present in this minority of patients.
CCTA was not performed in normal volunteers to
avoid unnecessary radiation exposure. Signiﬁcant
coronary artery disease was deemed to be unlikely in
this normal cohort, and epicardial fat volumes were
therefore only assessed and compared in Ob- and
Ln-T2D patients.
For assessment of liver disease, we have not used
liver biopsy, the current gold standard, because it is
invasive and limited by sampling and observer-
dependent variability (50). Instead, we used a
recently established, noninvasive, multiparametric
scanning method, which has demonstrated a high
diagnostic accuracy for the assessment of liver
ﬁbrosis, steatosis, and hemosiderosis (16).
Although the differences in mean peak systolic
strain and diastolic strain rates in Ln-T2D compared
with control subjects did not reach statistical signiﬁ-
cance, this may be due to the relatively small
sample size. Larger studies of Ln-T2D patients are
needed to conﬁrm this. Although the release of adi-
pokines including adiponectin and leptin has been
considered among the important actions of adipo-
cytes, we did not assess circulating levels of adipo-
nectin or leptin.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Dia-
betes is associated with abnormalities of cardiac
structure, energetics, and steatosis irrespective of BMI.
Ob-T2D patients have a greater propensity for ectopic
and visceral fat deposition, cardiac dysfunction,
ﬁbroinﬂammatory liver disease, and insulin resistance.
TRANSLATIONAL OUTLOOK: Further studies are
needed to delineate the mechanistic relationships
between ectopic and visceral adiposity, insulin resis-
tance, and cardiac dysfunction in patients with T2D.
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62There is evidence of a role for the sympathetic
nervous system in the relationship between insulin
and hypertension in obese patients with hyperten-
sion (51). We did not demonstrate any signiﬁcant
difference in resting heart rates or the systolic
blood pressure between the 2 diabetes groups to
suggest an enhanced adrenergic drive in the obese
group, but we did not assess circulating catechol-
amine levels.
Finally, the observational nature of our ﬁndings
precludes inferences of causality. Additional research
is necessary to further delineate the relationship be-
tween ectopic and visceral adiposity with potential
systemic effects such as insulin resistance and their
role in the development of cardiac dysfunction in
patients with T2D.
CONCLUSIONS
Ob-T2D patients show a greater propensity than Ln-
T2D patients for ectopic and visceral fat deposition
that is associated with cardiac contractile dysfunction
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